First-dose success with vardenafil in men with erectile dysfunction and associated comorbidities: RELY-I

L. Valiquette, F. Montorsi, S. Auerbach

Research output: Contribution to journalArticle

Abstract

First-dose success of phosphodiesterase type 5 (PDE5) inhibitors may be adversely affected in patients with comorbidities. This article reports first-dose success rates for vardenafil 10mg in men with erectile dysfunction (ED) and associated comorbidities who participated in the challenge phase of the Reliability -Vardenafil for Erectile Dysfunction I study. This study involved an open-label, single-dose, 1-week challenge period where patients who achieved SEP-2 (penetration) success were randomised to vardenafil 10mg or placebo for 12weeks in a double-blind manner. The first-dose success rates for SEP-2 and SEP-3 (maintenance of erection to completion of intercourse) were stratified according to comorbidities. Safety was assessed using adverse events (AEs). Of 600 men who received a single 10mg dose of vardenafil, 32% had hypertension, 16% had diabetes and 19% had dyslipidaemia. Vardenafil demonstrated overall effectiveness, including first-dose SEP-2 and SEP-3 success rates in patients with and without specific comorbidities. Initial overall success rates for SEP-2 and SEP-3 during the challenge phase were 87% and 74% respectively. First-dose SEP-2 and SEP-3 success rates were 84% and 66% in men with hypertension (n = 191); 84% and 72% in men with dyslipidaemia (n = 116); and 75% and 58% in men with diabetes (n = 95). Vardenafil was well tolerated and most AEs, including the most frequently reported flushing (3.5%), were mild to moderate in intensity. Vardenafil 10mg is generally well tolerated and efficacious, providing first-dose success with a consistently high rate of reliability of penetration and maintenance of erection in men with ED and associated comorbidities.

Original languageEnglish
Pages (from-to)1378-1385
Number of pages8
JournalInternational Journal of Clinical Practice
Volume60
Issue number11
DOIs
Publication statusPublished - Nov 2006

Fingerprint

Erectile Dysfunction
Comorbidity
Dyslipidemias
Maintenance
Hypertension
Phosphodiesterase 5 Inhibitors
Vardenafil Dihydrochloride
Placebos
Safety

Keywords

  • Comorbidities
  • Erectile dysfunction
  • Erection
  • First-dose success
  • PDE5 inhibitors
  • Vardenafil

ASJC Scopus subject areas

  • Medicine(all)

Cite this

First-dose success with vardenafil in men with erectile dysfunction and associated comorbidities : RELY-I. / Valiquette, L.; Montorsi, F.; Auerbach, S.

In: International Journal of Clinical Practice, Vol. 60, No. 11, 11.2006, p. 1378-1385.

Research output: Contribution to journalArticle

@article{45d92b03865b47fe942566a9a0de7b30,
title = "First-dose success with vardenafil in men with erectile dysfunction and associated comorbidities: RELY-I",
abstract = "First-dose success of phosphodiesterase type 5 (PDE5) inhibitors may be adversely affected in patients with comorbidities. This article reports first-dose success rates for vardenafil 10mg in men with erectile dysfunction (ED) and associated comorbidities who participated in the challenge phase of the Reliability -Vardenafil for Erectile Dysfunction I study. This study involved an open-label, single-dose, 1-week challenge period where patients who achieved SEP-2 (penetration) success were randomised to vardenafil 10mg or placebo for 12weeks in a double-blind manner. The first-dose success rates for SEP-2 and SEP-3 (maintenance of erection to completion of intercourse) were stratified according to comorbidities. Safety was assessed using adverse events (AEs). Of 600 men who received a single 10mg dose of vardenafil, 32{\%} had hypertension, 16{\%} had diabetes and 19{\%} had dyslipidaemia. Vardenafil demonstrated overall effectiveness, including first-dose SEP-2 and SEP-3 success rates in patients with and without specific comorbidities. Initial overall success rates for SEP-2 and SEP-3 during the challenge phase were 87{\%} and 74{\%} respectively. First-dose SEP-2 and SEP-3 success rates were 84{\%} and 66{\%} in men with hypertension (n = 191); 84{\%} and 72{\%} in men with dyslipidaemia (n = 116); and 75{\%} and 58{\%} in men with diabetes (n = 95). Vardenafil was well tolerated and most AEs, including the most frequently reported flushing (3.5{\%}), were mild to moderate in intensity. Vardenafil 10mg is generally well tolerated and efficacious, providing first-dose success with a consistently high rate of reliability of penetration and maintenance of erection in men with ED and associated comorbidities.",
keywords = "Comorbidities, Erectile dysfunction, Erection, First-dose success, PDE5 inhibitors, Vardenafil",
author = "L. Valiquette and F. Montorsi and S. Auerbach",
year = "2006",
month = "11",
doi = "10.1111/j.1742-1241.2006.01170.x",
language = "English",
volume = "60",
pages = "1378--1385",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - First-dose success with vardenafil in men with erectile dysfunction and associated comorbidities

T2 - RELY-I

AU - Valiquette, L.

AU - Montorsi, F.

AU - Auerbach, S.

PY - 2006/11

Y1 - 2006/11

N2 - First-dose success of phosphodiesterase type 5 (PDE5) inhibitors may be adversely affected in patients with comorbidities. This article reports first-dose success rates for vardenafil 10mg in men with erectile dysfunction (ED) and associated comorbidities who participated in the challenge phase of the Reliability -Vardenafil for Erectile Dysfunction I study. This study involved an open-label, single-dose, 1-week challenge period where patients who achieved SEP-2 (penetration) success were randomised to vardenafil 10mg or placebo for 12weeks in a double-blind manner. The first-dose success rates for SEP-2 and SEP-3 (maintenance of erection to completion of intercourse) were stratified according to comorbidities. Safety was assessed using adverse events (AEs). Of 600 men who received a single 10mg dose of vardenafil, 32% had hypertension, 16% had diabetes and 19% had dyslipidaemia. Vardenafil demonstrated overall effectiveness, including first-dose SEP-2 and SEP-3 success rates in patients with and without specific comorbidities. Initial overall success rates for SEP-2 and SEP-3 during the challenge phase were 87% and 74% respectively. First-dose SEP-2 and SEP-3 success rates were 84% and 66% in men with hypertension (n = 191); 84% and 72% in men with dyslipidaemia (n = 116); and 75% and 58% in men with diabetes (n = 95). Vardenafil was well tolerated and most AEs, including the most frequently reported flushing (3.5%), were mild to moderate in intensity. Vardenafil 10mg is generally well tolerated and efficacious, providing first-dose success with a consistently high rate of reliability of penetration and maintenance of erection in men with ED and associated comorbidities.

AB - First-dose success of phosphodiesterase type 5 (PDE5) inhibitors may be adversely affected in patients with comorbidities. This article reports first-dose success rates for vardenafil 10mg in men with erectile dysfunction (ED) and associated comorbidities who participated in the challenge phase of the Reliability -Vardenafil for Erectile Dysfunction I study. This study involved an open-label, single-dose, 1-week challenge period where patients who achieved SEP-2 (penetration) success were randomised to vardenafil 10mg or placebo for 12weeks in a double-blind manner. The first-dose success rates for SEP-2 and SEP-3 (maintenance of erection to completion of intercourse) were stratified according to comorbidities. Safety was assessed using adverse events (AEs). Of 600 men who received a single 10mg dose of vardenafil, 32% had hypertension, 16% had diabetes and 19% had dyslipidaemia. Vardenafil demonstrated overall effectiveness, including first-dose SEP-2 and SEP-3 success rates in patients with and without specific comorbidities. Initial overall success rates for SEP-2 and SEP-3 during the challenge phase were 87% and 74% respectively. First-dose SEP-2 and SEP-3 success rates were 84% and 66% in men with hypertension (n = 191); 84% and 72% in men with dyslipidaemia (n = 116); and 75% and 58% in men with diabetes (n = 95). Vardenafil was well tolerated and most AEs, including the most frequently reported flushing (3.5%), were mild to moderate in intensity. Vardenafil 10mg is generally well tolerated and efficacious, providing first-dose success with a consistently high rate of reliability of penetration and maintenance of erection in men with ED and associated comorbidities.

KW - Comorbidities

KW - Erectile dysfunction

KW - Erection

KW - First-dose success

KW - PDE5 inhibitors

KW - Vardenafil

UR - http://www.scopus.com/inward/record.url?scp=33749859517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749859517&partnerID=8YFLogxK

U2 - 10.1111/j.1742-1241.2006.01170.x

DO - 10.1111/j.1742-1241.2006.01170.x

M3 - Article

C2 - 17073835

AN - SCOPUS:33749859517

VL - 60

SP - 1378

EP - 1385

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 11

ER -